Enasidenib Mesylate vs Trastuzumab

## Enasidenib Mesylate vs Trastuzumab: Overview

This comparison examines the pharmacological differences between **Enasidenib Mesylate** and **Trastuzumab**.

## Mechanism of Action

**Trastuzumab**: Anti-HER2 monoclonal antibody inhibiting receptor signaling.

## Pharmacokinetics

**Half-life**: Enasidenib Mesylate — N/A; Trastuzumab — 28 days.

## Chemical Properties

**Type**: Enasidenib Mesylate — Small molecule; Trastuzumab — Antibody.